|
市場調査レポート
商品コード
1126401
陽子線治療の世界市場規模、シェア、産業動向分析レポート:製品タイプ別、適応症別(CNS癌、前立腺癌、頭頸部癌、乳癌、その他)、エンドユーザー別、地域別展望と予測、2022年~2028年Global Proton Therapy Market Size, Share & Industry Trends Analysis Report By Product Type, By Indication (CNS Cancer, Prostate Cancer, Head & Neck Cancer, Breast Cancer and Others), By End User, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
陽子線治療の世界市場規模、シェア、産業動向分析レポート:製品タイプ別、適応症別(CNS癌、前立腺癌、頭頸部癌、乳癌、その他)、エンドユーザー別、地域別展望と予測、2022年~2028年 |
出版日: 2022年08月31日
発行: KBV Research
ページ情報: 英文 244 Pages
納期: 即納可能
|
陽子線治療の世界市場規模は、予測期間中にCAGR12.5%の市場成長率で上昇し、2028年には9億6360万米ドルに達すると予測されます。
大半は、悪性腫瘍の増殖療法に使用されます。X線照射は陽子線によって散逸され、周囲の健康な組織へのダメージが少ないことが保証されます。陽子線治療と呼ばれる放射線療法は、がんの治療に最も頻繁に使用されています。従来の放射線治療と比較すると、効果や副作用が限定的であるという点で重要な利点があります。
陽子線治療はシンプルで安全な治療法であり、患者さんの幸福感を維持し、日常的な運動を速やかに再開させることができます。医療専門家は、周囲の健康な組織や臓器に深刻な害を与えることなく、原発巣を完全に根絶するために、全線量またはそれ以上の治療量を投与することが可能です。
COVID-19の影響分析
COVID-19パンデミックは、医療機器分野、特に粒子線治療装置に世界的に影響を及ぼしています。COVID-19パンデミック中の粒子線治療処置の実施は、地域によって大きく異なります。政府や当局がCOVID-19患者のためにリソースを利用できるように保証するために取り組んでいるため、いくつかの選択的手術が一時的に延期され、陽子線治療の市場に影響を与えると予想されます。世界的に癌の負担が増加することが予測されています。診断と治療手順の遅れがその原因となっています。
市場成長要因
粒子線治療と比較した陽子線治療の利点
陽子線治療では、近年かなりの技術的躍進が見られます。これらの開発により、メーカーはより侵襲性が低く、より効果的で、健康な組織への放射線被曝が少なく、副作用も少ない陽子線治療システムを開発することができました。がん細胞や腫瘍をより正確に狙い撃ちすることができます。発生するエネルギー量が少なく、被ばく量も少ないため、周辺の健康な組織や臓器に影響を与える可能性が低いです。
発展途上国における医療費の増加
各国の政府によるヘルスケア分野への投資の増加と規模は、市場の拡大を促進する要因の一つとなっています。新興諸国では、急速な経済成長と医療費の増加により、質の高いヘルスケアを利用できる国が増えると予想されています。これは陽子線治療分野にとって有望な成長の兆しと見なされています。これらの国々では、がんの発生率が上昇しているため、さまざまな放射線療法や機器のニーズが高まっています。
市場抑制要因
陽子線治療の手術中に腫瘍を確認することは困難です。
陽子線治療手術中に腫瘍を健康な正常組織と区別して可視化できないことは、遭遇する最大の問題の1つです。しかし、腫瘍はその構造を定期的に変化させるため、周囲の組織を傷つけずに悪性腫瘍の突出部だけに放射線を当てることは非常に困難です。放射線技師は、これを軽減するために、腫瘍の周囲に安全域を設けています。さらに、隣接する健康な組織へのダメージを減らすために照射範囲を限定する必要があり、腫瘍細胞を破壊するために必要な治療サイクルの回数が多くなってしまいます。
製品タイプの展望
陽子線治療市場は、製品タイプによって、加速器、ビーム輸送システム、ビーム伝送システム、ノズルおよび画像ビューア、患者位置決めシステムに区分されます。加速器セグメントは、2021年の陽子線治療市場で最大の収益シェアを獲得しました。陽子線治療市場の成長は、癌の発生率の上昇、輸入された放射性トレーサーに対するコスト面の利点、最先端の診断ツールの利用しやすさによってさらに後押しされています。陽子線治療は、水素原子を加速器で分解し、陽子と電子を分離し、分離された陽子を加速して安全なエネルギーに変換する治療法です。
適応症の展望
陽子線治療市場は、適応症別に頭頸部がん、中枢神経系がん、前立腺がん、乳がん、その他に分類されます。2021年の陽子線治療市場では、頭頸部がん分野が大きな収益シェアを占めました。陽子粒子は出口線量を発生させないため、腫瘍から遠く離れた場所にある正常組織は陽子線治療中に温存することができます。頭頸部領域のほぼすべてのがんに存在する解剖学的制限のため、これはこれらの腫瘍に非常に有用です。
エンドユーザーの展望
陽子線治療市場は、エンドユーザー別に、病院、陽子線治療センター、その他に分けられます。病院セグメントは、2021年の陽子線治療市場で最も高い収益シェアを調達しました。がんの有病率の上昇、病院インフラの改善、ハイテク機器の使用、病気に対する自己認識の高まりなどから、予測期間中もこの傾向が続くと予想されます。
地域別の展望
陽子線治療市場は、地域別に見ると、北米、欧州、アジア太平洋、LAMEAで分析されています。北米地域は、2021年に陽子線治療市場で最大の収益シェアを獲得しました。当面の間、優位性は持続すると予測されます。これは、強力なヘルスケアシステム、高齢者患者の増加、ヘルスケアシステムにおける有利な診療報酬規制、陽子線治療を提供するヘルスケア施設の増加などに起因しています。
List of Figures
The Global Proton Therapy Market size is expected to reach $963.6 million by 2028, rising at a market growth of 12.5% CAGR during the forecast period.
Proton radiation devices are used in proton therapy, sometimes referred to as proton radiotherapy and proton beam therapy. Utilizing proton treatment, cancer cells are destroyed. In proton therapy, a beam of protons is directed towards the tumors using proton accelerators. Protons are ionized protons that damage cells' DNA and cause cell death by interfering with it.
Equipment for proton therapy is expensive and takes up a lot of space. It includes electro-magnets, accelerators, gantries, nozzles, and patient rooms. High-energy beams are used in proton treatment, also known as proton radiation, to treat malignancies. A precise dose of high-energy radiation is kept inside the target tumor using this procedure.
The majority of the time, it is used in the treatment of malignant growth therapy. X-beam radiation is dissipated by protons, ensuring less damage to the surrounding healthy tissues. Radiation therapy called proton therapy is most frequently used to treat cancer. When compared to conventional radiation therapy, it offers important advantages in terms of effectiveness and limited side effects.
It is a simple, safe procedure that maintains patients' happiness and enables them to quickly resume routine exercises. It enables medical professionals to administer full or greater therapy doses that completely eradicate the primary tumor spot without seriously harming surrounding healthy tissue or organs.
Covid-19 Impact Analysis
The COVID-19 pandemic has affected the medical equipment sector globally, especially particle treatment devices. The administration of particle treatment procedures during the COVID-19 pandemic varies greatly from location to region. The temporary deferral of several elective surgeries is anticipated to affect the market for proton therapy as governments and authorities work to guarantee that resources are available for COVID-19 patients. It is predicted to increase the worldwide cancer burden. The delay in diagnosis and treatment procedures is to blame for this.
Market Growth Factors
Benefits of proton therapy compared to particle therapy
Proton treatment has seen considerable technological breakthroughs in recent years. These developments have aided manufacturers in creating less invasive, more effective, and regulated proton treatment systems that also cause less radiation exposure to healthy tissues and have fewer adverse effects. More precisely targets cancer cells and tumors. A less amount of energy is produced, and there is a smaller exit dose, lowering the possibility of harm to the nearby healthy tissues and organs.
Rising healthcare spending in developing nations
The increasing number and size of investments made in the healthcare sector by governments of various nations is one of the key drivers fuelling the market's expansion. Due to their rapid economic growth and rising healthcare costs, it is projected that the availability of high-quality healthcare would increase in several developing countries. This is regarded as a promising sign of growth for the proton therapy sector. The rising incidence of cancer in these countries has increased the need for various radiation therapies and equipment.
Market Restraining Factors
Tumors are difficult to see during proton treatment operations.
The inability to distinguish tumors from healthy normal tissue and to visualize them during proton treatment procedures is one of the biggest problems encountered. It becomes extremely challenging to only radiate the malignant protrusion without damaging the surrounding tissues, though, because tumors can change their structure regularly. Radiologists place a safety margin around the tumor to reduce this. Additionally, it becomes imperative to restrict the radiation dose range to reduce the harm to the adjacent healthy tissue, which raises the number of treatment cycles required to destroy tumorous cells.
Product Type Outlook
Based on the Product Type, the Proton Therapy Market is segmented into Accelerator, Beam Transport systems, Beam Delivery systems, Nozzle and Image Viewers, and Patient Positioning System. The accelerator segment garnered the largest revenue share in the proton therapy market in 2021. Proton therapy market growth is further aided by the rising incidence of cancer, cost advantages over imported radioactive tracers, and accessibility of cutting-edge diagnostic tools. Starting with a hydrogen atom, the accelerator splits it apart, separates the proton from the electron, and then accelerates the isolated proton to carry as much energy as is safe.
Indication Outlook
On the basis of Indication, the Proton Therapy Market is divided into Head and Neck Cancer, CNS Cancer, Prostate Cancer, Breast Cancer, and Others. The head and neck cancer segment witnessed a significant revenue share in the proton therapy market in 2021. Since proton particles do not generate exit dosage, normal tissues located far from the tumor can be spared during proton therapy. Due to the anatomical restrictions present in almost all cancers in the head and neck region, this is very helpful for these tumors.
End User Outlook
By End-User, the Proton Therapy Market is divided into Hospitals, Proton Therapy Centers, and Others. The hospital segment procured the highest revenue share in the proton therapy market in 2021. Due to the rise in the prevalence of cancer, improvements in the hospital infrastructure, the use of high-tech equipment, and increased self-awareness about diseases, it is anticipated that this trend will continue during the projected period.
Regional Outlook
Region-wise, the Proton Therapy Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region acquired the largest revenue share in the proton therapy market in 2021. During the foreseeable term, dominance is anticipated to persist. This was ascribed to a strong healthcare system, a growth in elderly patients, favorable reimbursement regulations in the healthcare system, and an increase in the number of healthcare facilities that provide proton treatment..
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Toshiba Corporation, Siemens Healthineers AG (Siemens AG), Ion Beam Applications SA, Hitachi, Ltd., Mirion Technologies, Inc., Mevion Medical Systems, Inc., Provision Healthcare, Sumitomo Corporation and Optivus Proton Therapy, Inc.
Strategies Deployed in Proton Therapy Market
May-2022: Sun Nuclear Corporation, a subsidiary of Mirion Technologies unveiled SunSCAN 3D cylindrical water scanning system for beam scanning, linear accelerator commissioning, and annual Quality Assurance in Radiation Therapy. The new SunSCAN 3D water scanning system is an advanced addition to Sun Nuclear's complete solutions offering for independent, combined Quality Management of Diagnostic Imaging and Radiation Therapy.
May-2022: Ion Beam Applications took over Modus Medical Devices, a Canadian company based in London. With this acquisition, IBA would profit from synergies both in R&D and in sales and promote it to expand its product roster. Additionally, the acquisition would reinforce IBA's competitive standing globally along with its footprint in North America.
Mar-2022: Ion Beam Applications came into a partnership with Tractebel, a global engineering business. This partnership would sustain IBA's consumers with their proton therapy technique and construction schemes. Additionally, IBA would advertise Tractebel's consulting services to its future consumers connecting to the design and construction of their proton treatment facilities.
Nov-2021: Mirion Technologies completed the acquisition of CHP Dosimetry, a U.S.-based supplier of dosimetry services. The new CHP Dosimetry would continue to operate Mirion's strong dosimetry products.
Oct-2021: IBA introduced Campus, the world's first online platform committed to proton therapy. The new Campus allows consumers to share proton therapy-related materials and resources, along with conversation forums with other users, to assist researchers and clinicians in proton therapy to improve and discover new skills for the advantage of patients.
Oct-2021: IBA formed a partnership with RaySearch Laboratories, a world head in software for radiation therapy. Through this partnership, the companies aimed to expand their partnership in proton treatment within the regions of FLASH radiotherapy, proton ARC therapy, and therapy of moving tumors. Additionally, the RayCare oncology information system from RaySearch would be tailored for optimal benefit in conjunction with the IBA delivery solutions.
Sep-2021: Siemens Healthineers joined hands with The University of Texas MD Anderson Cancer Center. Through this collaboration, the companies aimed to develop a global education program focused on promoting the performance of consistent, high-quality magnetic resonance (MR) imaging in radiation oncology. Additionally, the program would deliver courses for both clinical and executive groups to promote secure adoption and wider clinical execution of MR to enhance outcomes for patients.
Apr-2021: Siemens Healthineers took over Varian Medical Systems, an American radiation oncology therapies, and software maker. With this acquisition, Siemens Healthineers has the most complete offering in the MedTech sector, which delivers the business's significant potential for value creation. Additionally, with a highly combined process, Siemens Healthineers would take the global battle against cancer to another level.
Sep-2020: Mevion Medical Systems signed an agreement with Proton International, a professional team committed to bringing Proton Therapy to organizations and patients. Through this agreement, the companies aimed to provide Mevion's close proton therapy solution to new centers in locations such as South Texas and the Southeast United States. Additionally, the new centers would offer the MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS). HYPERSCAN allows quicker and sharper delivery of therapeutic radiation to tumors.
Jan-2018: Hitachi Healthcare Americas took over VidiStar, a Greenville, S.C.-based business. Through this acquisition, VidiStar would advance the organization's informatics strategy and analytics abilities to enhance workflow and intelligence for physicians, specifically with those providers completing diagnostic ultrasound examinations.
Market Segments covered in the Report:
By Product Type
By Indication
By End User
By Geography
Companies Profiled
Unique Offerings from KBV Research